1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Bavarian Nordic A/S
  6. Summary
    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
Real-time Estimate Cboe Europe  -  05/23 07:05:47 am EDT
214.30 DKK   -1.06%
04:16aBavarian Nordic A/S - Articles of Association
GL
04:16aBavarian Nordic A/S - Articles of Association
GL
03:47aCapital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
05/17/2022 05/18/2022 05/19/2022 05/20/2022 05/23/2022 Date
135.65(c) 141.35(c) 183(c) 216.6(c) 214.8 Last
344 064 671 760 2 915 017 4 240 642 2 238 252 Volume
+4.19% +4.20% +29.47% +18.36% -0.83% Change
More quotes
Estimated financial data (e)
Sales 2022 1 678 M 238 M 238 M
Net income 2022 -1 676 M -237 M -237 M
Net cash position 2022 1 050 M 149 M 149 M
P/E ratio 2022 -9,06x
Yield 2022 -
Sales 2023 3 328 M 472 M 472 M
Net income 2023 12,4 M 1,76 M 1,76 M
Net cash position 2023 942 M 133 M 133 M
P/E ratio 2023 1 632x
Yield 2023 -
Capitalization 15 233 M 2 159 M 2 159 M
EV / Sales 2022 8,45x
EV / Sales 2023 4,29x
Nbr of Employees 759
Free-Float 99,7%
More Financials
Company
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (98.1%) and services (1.9%). Net sales are distributed geographically as follows: the United States (56.2%), Belgium (13.9%), Germany (13.6%), Netherlands (4%), Sweden... 
Sector
Pharmaceuticals
Calendar
08/24Earnings Release
More about the company
Ratings of Bavarian Nordic A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BAVARIAN NORDIC A/S
04:16aBavarian Nordic A/S - Articles of Association
GL
04:16aBavarian Nordic A/S - Articles of Association
GL
03:47aCapital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
03:47aCapital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
GL
05/19Britain offers smallpox shot as monkeypox cases spread in Europe
RE
05/19Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox C..
GL
05/19Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox C..
CI
05/18Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Term..
GL
05/18Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Term..
AQ
05/18Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exerci..
GL
05/18Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exerci..
GL
05/18Bavarian Nordic A/S Announces to Manufacture First Freeze-Dried Doses of Smallpox Vacci..
CI
05/09TRANSCRIPT : Bavarian Nordic A/S, Q1 2022 Earnings Call, May 09, 2022
CI
05/09Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
GL
05/09Bavarian Nordic Announces Interim Results for the First Three Months of 2022
GL
More news
News in other languages on BAVARIAN NORDIC A/S
04:41aACTUALIZACIÓN DE LAS GRANDES EVOLUCI : los aerogeneradores giran con fuerza, Leoni se tamb..
04:22aPOINT SUR LES FORTES VARIATIONS DU J : les éoliennes tournent fort, Leoni flanche
05/20POINT SUR LES FORTES VARIATIONS DU J : fin de semaine calme sur les marchés européens
05/20Anleger spekulieren mit Bavarian Nordic wegen Affenpocken
05/20AKTIEN EUROPA : Erholung mit Rückenwind aus China
More news
Analyst Recommendations on BAVARIAN NORDIC A/S
More recommendations
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 216,60 DKK
Average target price 355,17 DKK
Spread / Average Target 64,0%
EPS Revisions
Managers and Directors
Paul Chaplin President & Chief Executive Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Gerardus Wilhelmus van Odijk Chairman
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Russell Thirsk Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BAVARIAN NORDIC A/S-19.42%2 159
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707